Intra-Cellular Therapies, Inc. Form 3 September 09, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549 OMB

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Alafi Christopher D			2. Date of Event Requiring Statement (Month/Day/Year)	<sup>3</sup> 3. Issuer Name <b>and</b> Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [NONE]				
(Last)	(First)	(Middle)	08/29/2013	4. Relationsh Person(s) to	nip of Reporting Issuer	g 5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O ALAFI CAPITAL COMPANY, LLC, 8 ADMIRAL DRIVE, SUITE 324				X Directo		o Owner		
(Street) EMERYVILLE, CA 94608			OfficerOther (give title below) (specify below)			of marriadar of boling of oup		
EWIEKT VILLE,A C		<b>1</b> 9 <del>1</del> 000				Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Secu (Instr. 4)	rity		2. Amount Beneficiali (Instr. 4)	of Securities y Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Common St	ock		3,542,88	5	Ι	Held by Alafi Capital Company, LLC $(1)$		
Common St	ock		503,753		Ι	Held as Trustee of The Moshe H. Alafi and Margaret E. Alafi Generation-Skipping Trust (2)		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.					SEC 1473 (7-02	2)		

owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

OMB APPROVAL

3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

1. Title of Derivative Security (Instr. 4)		2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Amount or		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Title	Number of Shares		or Indirect (I) (Instr. 5)			
	Stock Option (right to buy)	( <u>3)</u>	05/30/2023	Common Stock	9,375	\$ 3.26	D	Â	
	Stock Option (right to buy)	(4)	05/30/2023	Common Stock	20,000	\$ 3.26	D	Â	

r

## Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Alafi Christopher D C/O ALAFI CAPITAL COMPANY, LLC 8 ADMIRAL DRIVE, SUITE 324 EMERYVILLE, CA 94608	ÂX	ÂX	Â	Â		
Signatures						
/s/ Lawrence J. Hineline, Attorney-in-fact	09/09/2013					
**Signature of Reporting Person	Dat	e				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Dr. Alafi is a managing partner of Alafi Capital Company, LLC and may be deemed to beneficially own the shares held by Alafi Capital
(1) Company, LLC. Dr. Alafi disclaims beneficial ownership of the securities held by Alafi Capital Company, LLC except to the extent of his pecuniary interest therein.

- (2) Dr. Alafi is the Trustee of The Moshe H. Alafi and Margaret E. Alafi Generation-Skipping Trust. Dr. Alafi disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein, if any.
- (3) The option vests as to 50% of the shares on May 31, 2014 and 50% of the shares on May 31, 2015.
- (4) The option vests as to 50% of the shares on July 1, 2014 and 50% of the shares on July 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.